Q-linea AB has the GF Score of 68, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Q-linea AB
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Q-linea AB (CHIX:QLINEs) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Q-linea AB GF Score Related Terms
CHIX:QLINES vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Q-linea AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's GF Score distribution charts can be found below:
* The bar in red indicates where Q-linea AB's GF Score falls into.
Q-linea AB (CHIX:QLINES) has a GF Score of 68 as of Jul. 05, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Q-linea AB and its competitors. This is 74% above median its historical median of 39.00. Over the past decade, Q-linea AB's GF Score has ranged from 8.00 to 73.00.
Is Q-linea AB's GF Score too high?
Q-linea AB's current GF Score of 68 is 74% above median its 10-year median of 39.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 73.00. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's GF Score compare to ABT and SYK?
Q-linea AB's GF Score of 68 can be compared against companies in the Medical Devices & Instruments industry. Historically, Q-linea AB's own GF Score has ranged from 8.00 to 73.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Q-linea AB and its competitors. Q-linea AB's current GF Score is 68, which is 74% above median its own 10-year median of 39.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current GF Score of 68. The stock's GF Value™ is kr1,981.69, compared to a current price of kr1,610.00 — trading 18.8% below its estimated fair value. The current GF Score is 68, which is 74% above median its 10-year median of 39.00. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current GF Score is 68 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 18.8% below its estimated GF Value™ of kr1,981.69.
Key valuation signals for CHIX:QLINES:
GF Score: 68 (74% above median its 10-year median of 39.00)
GF Value™: kr1,981.69 vs. price of kr1,610.00 (18.8% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score
Get the complete analysis for CHIX:QLINES
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 